Bizarre Patents
Mountable Printable Placard With Headband
A resilient headband in a shape for being mounted on the head of the user. The headband is equipped with a longitudinal slotted member for holding a placard.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8106046 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disc... | 01/31/2012 |
| 8067447 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of f... | 11/29/2011 |
| 8034940 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): | 10/11/2011 |
| 8013004 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure ... | 09/06/2011 |
| 7994190 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of fo... | 08/09/2011 |
| 7989640 | Sulfonylpyrrolidine modulators of androgen receptor function and method Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1,... | 08/02/2011 |
| 7989433 | Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists The present invention provides compounds having the following Formula IA and IB, which are useful as MCHR1 antagonists, and includes prodrugs and pharmaceutically acceptable salts thereof: ... | 08/02/2011 |
| 7973159 | Non-basic melanin concentrating hormone receptor-1 antagonists The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compo... | 07/05/2011 |
| 7968718 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and proce... | 06/28/2011 |
| 7968577 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula ... | 06/28/2011 |
| 7956049 | Melanin concentrating hormone receptor-1 antagonists The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, ... | 06/07/2011 |
| 7951793 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; | 05/31/2011 |
| 7943658 | Indole indane amide compounds useful as CB2 agonists and method Indole indane amides which are CB2 agonists are provided which have the structure wherein R1, R2, R3, R4 and R5 are as defined herein, which compounds are useful in tre... | 05/17/2011 |
| 7910747 | Phosphonate and phosphinate pyrazolylamide glucokinase activators Pyrazoloamides are provided which are phosphonate and phosphinate glucokinase activators that are useful in treating diabetes and related diseases and have the structure wherein i... | 03/22/2011 |
| 7910583 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy... | 03/22/2011 |
| 7888504 | Glucokinase activators and methods of using same Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; | 02/15/2011 |
| 7888381 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) | 02/15/2011 |
| 7858639 | Bicyclic heterocycles as cannabinoid-1 receptor modulators The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to... | 12/28/2010 |
| 7851622 | Non-basic melanin concentrating hormone receptor-1 antagonists The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compo... | 12/14/2010 |
| 7838678 | Process for preparing atazanavir bisulfate and novel forms A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A cryst... | 11/23/2010 |
| 7829720 | Process for preparing atazanavir bisulfate and novel forms A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A cryst... | 11/09/2010 |
| 7820702 | Sulfonylpyrrolidine modulators of androgen receptor function and method Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1,... | 10/26/2010 |
| 7812048 | Glucokinase activators and methods of using same Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is ... | 10/12/2010 |
| 7795291 | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method Compounds are provided which have the structure of Formula (I): wherein R1 is halogen; and X is hydrogen or halogen, and salts thereof, which compounds are useful as anti-atherosclerotic, anti-dyslipidemic, anti-... | 09/14/2010 |
| 7723355 | 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compo... | 05/25/2010 |
| 7709647 | Tetrahydroquinoline cannabinoid receptor modulators The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to... | 05/04/2010 |
| 7696241 | Bicyclic compounds as modulators of androgen receptor function and method The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for examp... | 04/13/2010 |
| 7659281 | HMG-CoA reductase inhibitors Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperl... | 02/09/2010 |
| 7655688 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds. ... | 02/02/2010 |
| 7629342 | Azabicyclic heterocycles as cannabinoid receptor modulators The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to... | 12/08/2009 |
| 7625923 | Bicyclic modulators of androgen receptor function The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for examp... | 12/01/2009 |
| 7598262 | Method for treating diabetes A method is provided for first line treatment of type 2 diabetes employing a combination of metformin and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post... | 10/06/2009 |
| 7589193 | C-aryl glucoside SGLT2 inhibitors and method A compound of the formula I A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent. ... | 09/15/2009 |
| 7589088 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods Compounds are provided having the formula (I) wherein R, B, X and Y are as defined herein. ... | 09/15/2009 |
| 7579479 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m, and ... | 08/25/2009 |
| 7553836 | Melanin concentrating hormone receptor-1 antagonists The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b | 06/30/2009 |
| 7550445 | Aripiprazole complex formulation and method An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible general... | 06/23/2009 |
| 7521557 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases. ... | 04/21/2009 |
| 7507838 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones A process for preparing Z-5-carboxymethylene-1,3-dioxolan-4-ones is provided which includes the steps of reacting a bis-ketal or bis-acetal of tartaric acid with a potassium containing base to form the carboxymethylene-1,3-dioxolan-4-one. A process for preparing HIV... | 03/24/2009 |
| 7507823 | Process of making aripiprazole particles A method of preparation of crystalline aripiprazole monohydrate includes the use of solution enhanced dispersion by supercritical fluid. Specifically, water is introduced to a stream of supercritical fluid which is then allowed to mix with a stream including a mixtu... | 03/24/2009 |
